Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether MIS416 administered once weekly over 12
months is safe, tolerable, and improves a range of signs and symptoms associated with
secondary progressive multiple sclerosis.